September 27th 2024
Dupilumab represents the first new treatment approach for uncontrolled COPD in more than a decade and reduced disease exacerbations by 34% in clinical trials.
Medical Crossfire®: What Are Effective Strategies for Onco-Nurses to Improve Outcomes in Patients with Small Cell Lung Cancer?
View More
Satellite Symposia at the Annual Radiation Oncology Meeting
September 28-29, 2024
Register Now!
Community Practice Connections: 7th Annual School of Nursing Oncology™
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Lung Cancer Tumor Board: Enhancing Precision Medicine in NSCLC Through Advancements in Molecular Testing and Optimal Therapy Selection
View More
Virtual Show Me the Data™: How HER2, HER3, and TROP2 Targeted Strategies Will Impact Evolving Paradigms in NSCLC
View More
6th Annual Advanced Practice Collaborative
View More
Community Practice Connections™: 24th Annual International Lung Cancer Congress®
View More
42nd Annual CFS: Innovative Cancer Therapy for Tomorrow®
November 13-15, 2024
Register Now!
19th Annual New York Lung Cancers Symposium®
November 16, 2024
Register Now!
Let’s Get “Real”: Alpha-1 Antitrypsin Deficiency—Case-Based Perspectives on Managing Associated Emphysema
View More
Shaping the Management of COPD with Biologic Therapy
View More
Elevating Care for PAH: Applying Recommended Management Approaches to Maximize Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
EGPA: Highlighting the Patient Journey to Improve the Differential Diagnosis and Accelerate the Initiation of Guideline-Based Care
View More
Identifying Actionable Biomarkers in NSCLC: Real World Case Discussions on Applications of Testing in the Treatment Planning Process
View More
How CEACAM5 Expression Can Be Measured and Leveraged in NSCLC Care: Current Developments & Future Therapeutic Opportunities
View More
Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!
View More
Lung Cancer Tumor Board®: Enhancing Multidisciplinary Communication to Optimize Immunotherapy in Stage I-III NSCLC
View More
Matching Treatment to Patient with EGFR-Mutant Lung Cancer: Mutation Subtypes, Co-Mutations, and Managing Resistance
View More
Improving Outcomes Across Frontline and R/R SCLC Care in Community Treatment Settings
View More
Clinical ShowCase™: Finding the Best Path Forward for Patients with COPD
View More
Annual Hawaii Cancer Conference
January 25-26, 2025
Register Now!
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
18th Annual New York Lung Cancers Symposium®
View More
22nd Annual Winter Lung Cancer Conference®
January 31, 2025 - February 2, 2025
Register Now!
Dialogues With the Surgeon on Integration of Systemic Therapies in Perioperative Settings for NSCLC: Looking at EGFR, ALK, IO, and Beyond…
View More
21st Annual Winter Lung Cancer Conference® In Line Session: Advent of TROP2-Directed ADCs In Lung Cancer
View More
LIVE! Testing Board®: Breaking Down Pathologic Reports to Identify Actionable Markers in Patients with NSCLC
View More
Charting the Path to Precision Diagnosis: Detection and Treatment Approaches for Oncogenic Mutations in NSCLC
View More
Investigational Oral Antiviral Ensitrelvir Reduces Time to Resolution of Common COVID-19 Symptoms
April 10th 2023Recent research shows that patients with mild-to-moderate COVID-19 who received ensitrelvir within 5 days of symptom onset saw their symptoms resolve a day earlier than those who received placebo.